Le Lézard
Classified in: Health, Covid-19 virus
Subject: MRR

Global Pharmaceuticals & Biotechnology Royalty Rates Report 2022 with Theory Associated with Deriving Royalty Rates


DUBLIN, May 23, 2022 /PRNewswire/ -- The "Royalty Rates for Pharmaceuticals & Biotechnology, 9th Edition" report has been added to ResearchAndMarkets.com's offering.

Research and Markets Logo

Royalty Rates for Pharmaceuticals & Biotechnology features more real-deal royalty rates, license fees, and milestone payment benchmarks than any other publication.

The ninth edition of Royalty Rates for Pharmaceuticals & Biotechnology contains hundreds of royalty rates and other financial compensation benchmarks that can be used to optimize the pricing of biotechnology and pharmaceutical innovations. You'll find updated and expanded information from past editions as well as an increased number of reported license agreements.

This new edition and the transaction details have been collected from well-established sources over a period of 22 years of research. Royalty Rates for Pharmaceuticals & Biotechnology provides real-deal information for hundreds of transactions, including the technology licensed, royalty rates, license fees, and milestone payments. And it goes well beyond the rates to provide context for each deal analyzed.

This unique resource is organized into two useful sections:

The first section covers the theory associated with deriving royalty rates.

An overview of intellectual property value is included along with seven methods that can be employed to derive royalty rates: Simple Rules of Thumb, Industry Guidelines, Discounted Cash Flow Analysis, Risk-Adjusted Net Present Value Analysis, Infringement Damages Analysis, Comparable License Transactions, Investment Rate of Return Analysis, and the Relief-From-Royalty Method.

The second section of this one-of-a-kind report presents detailed financial information from real-world transactions. 

You'll find information on the parties involved in the transactions along with a description of the technology exchanged and all financial details that could be discovered. This publication is designed to provide accurate and authoritative information about the subject matter covered. 

Key Topics Covered:

For more information about this report visit https://www.researchandmarkets.com/r/7fm5y6

Media Contact:

Research and Markets 
Laura Wood, Senior Manager 
[email protected] 

For E.S.T Office Hours Call +1-917-300-0470 
For U.S./CAN Toll Free Call +1-800-526-8630 
For GMT Office Hours Call +353-1-416-8900 

U.S. Fax: 646-607-1907 
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets


These press releases may also interest you

at 09:00
Amid growing concerns about a medical crisis as a result of acute conflict between the government...

at 08:45
Wolf Haldenstein Adler Freeman & Herz LLP  ("Wolf  Haldenstein") announces that a federal securities class action lawsuit has been filed in the United States District Court for the Southern  District of New York on behalf of investors who purchased...

at 08:00
Sunshine Biopharma Inc. , a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and antivirals, is happy to announce that its wholly owned generic pharmaceutical subsidiary, Nora...

at 07:00
The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against QuidelOrtho Corporation ("QuidelOrtho" or "the Company") for violations of 10(b) and 20(a) of the Securities...

at 07:00
YS Biopharma Co., Ltd. ("YS Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and...

at 06:40
The Gross Law Firm issues the following notice to shareholders of QuidelOrtho Corporation f/k/a Quidel Corporation . Shareholders who...



News published on and distributed by: